摘要
目的：探讨乳腺癌新辅助化疗疗效评价中动态增强MRI的价值。方法：新辅助化疗的乳腺癌患者26例，年龄34--70岁，平均55．2岁；化疗前后用同一动态增强扫描方案进行乳腺MR检查（GESigna1．5TMRI扫描仪）。参照实体瘤疗效评价标准（RECIST）进行影像评价，并与病理学检查（根据日本乳腺癌协会新辅助化疗病理反应性分级标准）对照。结果：MRI评价显示疾病稳定4例，部分反应19例，完全反应3例，无疾病进展病例。有效的22例全部证实属于病理反应有效，而无效的4例中也有l例属于病理反应有效；MRI评价新辅助化疗疗效的敏感度为95．7％（22／23），特异度为100％（3／3），阳性预测值为100％（22／22），阴性预测值为75％（3／4）。结论：动态增强MRI在使用RECIST标准对新辅助化疗疗效的评价准确度较高。
Purpose： To evaluate the role of dynamic contrast-enhanced magnetic resonance imaging （DCE-MRI） in assessing the tumor response to neoadjuvan chemotherapy （NAC） in breast cancer patients. Methods： Twenty-six patients with breast cancer received NAC were included. DCE - MRI was carried out on a 1.5 T scanner （GE, Signa Excite） before and after the NAC prior to the surgery. The age range was 34 to 70 （mean age 55.2 years）. Response evaluation was made by MRI analysis based on the response evaluation criteria in solid tumors（RECIST）, by which the MRI results and pathological examination results were compared （Japanese Breast Cancer Society Histopathological Criteria for Assessment of Therapeutic Response in Breast Cancer）. Results： With enhanced MRI, 3 complete responders （CR）, 19 partial responders （PR）, 4 non - responders, and cases with no progression were documented. In total 22 responders on MR/, all histology evaluation revealed pathologic responses; Among 4 non - responders on MRI, was with pathologic response. Sensitivity of MRI for response evaluation to NAC was 95.7%（22/23）, and specificity was 100% （3/3）, positive predictive value was 100% （22/22）, negative predictive value was 75% （3/4）. Conclusion： DCE-MRI is able to assess response more accurately in patients undergoing NAC for breast cancer by means of RECIST.
出处
《中国医学计算机成像杂志》
CSCD
北大核心
2013年第4期329-332,共4页
Chinese Computed Medical Imaging
